Trial of Afatinib (BIBW 2992) in Suspected or Confirmed Mutant EGFR Lung Cancer Patients Unfit for Chemotherapy

Trial Profile

Trial of Afatinib (BIBW 2992) in Suspected or Confirmed Mutant EGFR Lung Cancer Patients Unfit for Chemotherapy

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 19 Dec 2016

At a glance

  • Drugs Afatinib (Primary)
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Acronyms TIMELY
  • Most Recent Events

    • 26 Oct 2016 Planned End Date changed from 1 Aug 2016 to 1 Dec 2017.
    • 18 Sep 2015 Accrual to date is 105% according to the United Kingdom Clinical Research Network record.
    • 01 Sep 2015 Planned End Date changed from 1 Jun 2016 to 1 Aug 2016 as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top